Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $236000.0.

  • Fulcrum Therapeutics' Other Accumulated Expenses fell 4100.0% to $236000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $236000.0, marking a year-over-year decrease of 4100.0%. This contributed to the annual value of $463000.0 for FY2024, which is 1691.92% up from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Other Accumulated Expenses is $236000.0, which was down 4100.0% from $173000.0 recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Other Accumulated Expenses registered a high of $463000.0 during Q4 2024, and its lowest value of $9000.0 during Q1 2023.
  • Over the past 5 years, Fulcrum Therapeutics' median Other Accumulated Expenses value was $134000.0 (recorded in 2022), while the average stood at $187578.9.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Other Accumulated Expenses tumbled by 9328.36% in 2023, and later soared by 417777.78% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Other Accumulated Expenses (Quarter) stood at $74000.0 in 2021, then surged by 41.89% to $105000.0 in 2022, then skyrocketed by 277.14% to $396000.0 in 2023, then rose by 16.92% to $463000.0 in 2024, then tumbled by 49.03% to $236000.0 in 2025.
  • Its Other Accumulated Expenses was $236000.0 in Q3 2025, compared to $173000.0 in Q2 2025 and $441000.0 in Q1 2025.